Introduction
Nonunion fractures or tumour resections leading to large bone defects are clinical problems that affect hundreds of thousands of patients worldwide. As such defects do not heal spontaneously and usually lead to severe functional impairment, several therapeutic approaches including autologous bone transplantation, 1 implantation of different biomaterials 2 and application of cytokines, hormones or growth factors have been investigated. 3, 4 However, as yet there is still no effective therapy for most cases.
Bone morphogenetic protein-2 (BMP-2) is a potent osteoinductive factor, 5 which has been shown to induce osteogenic differentiation of mesenchymal cells. 6 The suitability of recombinant human BMP-2 (rhBMP-2) for the treatment of large-size bone defects has been evaluated thoroughly in different animal models. 7, 8 Although encouraging results were achieved with this and other recombinant BMPs, two of which have already successfully traversed clinical trials, several obstacles still have to be overcome. The production of rhBMPs is very expensive, and successful bone healing requires high amounts of protein, 9 which might spread throughout the patient's body with inadvertent accumulation in nontarget organs. Regional gene transfer may therefore provide a viable alternative to protein therapy. Recently, different gene therapy approaches to bone regeneration have been studied, suggesting the use of viral vectors such as adenoviruses [10] [11] [12] [13] [14] [15] [16] [17] and retroviruses 18, 19 as carriers of BMP-2 cDNA. Adenoviruses, although highly immunogenic and at higher doses toxic to several tissues, are generally considered as the most efficient gene transfer vehicles. 20 Furthermore, recent reports have demonstrated the healing of large bone defects in several small animal models following adenovirus-mediated transfer of BMP-2 cDNA. [12] [13] [14] [15] [16] [17] In these studies, the short-term expression of the transgene commonly observed with adenoviral vectors did not represent a disadvantage for the purpose of bone regeneration. However, this question will have to be addressed by further studies on large animal models. Nonviral gene delivery, although less efficient than the viral methods, may have several advantages over viruses, for example, ease of preparation, theoretically no limitation of the size of the DNA, less immunological and safety problems. 20 Nonviral vectors may therefore also be suitable for regional BMP-2 gene transfer, and comparative studies of the different vector types are required to identify the optimal gene transfer system for specific applications of regional gene therapy such as bone regeneration.
Apart from the vector, the choice of the target cells is also an important factor to be considered, especially for ex vivo gene transfer. Pluripotent mesenchymal cells can be differentiated into an osteoblastic lineage by stimulation with BMP-2. Previous studies showed that transfection of BMP-2-cDNA into a mesenchymal cell line stimulated the osteogenic pathway via autocrine and paracrine mechanisms in vitro and in vivo. 21, 22 In this study, we investigated the transplantation of BMP-2-producing primary rat bone marrow stromal cells (BMSC), modified by either liposomemediated or adenoviral BMP-2 gene transfer, into bone defects in vitro and in vivo and compared the two approaches with respect to the efficacy of bone regeneration.
Results

Efficacy of gene transfer into BMSC
The adenoviral vector AdCMVBMP-2 used in our previous studies 23, 24 and the liposome Metafectene, which had been identified among the liposomes LipofectAMINE, Metafectene and Geneshuttle as the most suitable for gene delivery into primary BMSC, were first evaluated in vitro with respect to the efficacy of gene transfer into BMSC. Optimization experiments were performed either with the adenoviral vector AdLacZ and the plasmid pLacZ, both carrying a b-galactosidase reporter gene, or with the adenoviral vector AdGFP and the plasmid pGFP, both carrying a green fluorescent protein reporter gene. The optimal virus dose was found to be 500 plaque forming units (PFU)/cell, while the optimal amount of DNA for liposome-mediated transfection was 1.5 mg/1.5 Â 10 5 cells with an optimal liposome: DNA ratio of 4 ml/mg of DNA (data not shown). Adenoviral gene transfer regularly resulted in an approximately two-fold greater number of positive cells than liposome-mediated gene delivery (Figure 1a-d ), but transgene expression lasted for at least 14 days irrespective of the gene transfer method used, as determined by FACS analysis of GFP-positive cells (data not shown). The differences in the gene transfer efficacy could not be Bone regeneration by cell-mediated BMP-2 gene transfer J Park et al overcome by changing the concentration of the DNA or the DNA/liposome ratio, which indicated a generally lower efficacy of the liposomal vector compared with the adenovirus. In subsequent experiments the reporter gene was replaced by human BMP-2 cDNA, and the adenoviral vector AdCMVBMP-2 was compared with lipid-DNA complexes containing the plasmid pCMVBMP-2, which carries exactly the same transgene cassette as AdCMVBMP-2. This comparison was performed by transfecting the BMP-2 cDNA into the same number of primary BMSC on the same tissue culture plate using either 500 PFU/cell of the adenoviral vector or 1.5 mg of the plasmid, followed by detection of the BMP-2 protein by immunohistochemistry 3 days after gene delivery ( Figure 2 ). Gene transfer with AdCMVBMP-2 resulted in an even distribution of infected cells throughout the culture vessel, while gene delivery with liposomes only led to focal populations of BMP-2-producing cells ( Figure 2 , lower panels). The amount of BMP-2 protein secreted by these cells was quantified in the supernatants collected in 24-h intervals after the gene transfer by ELISA. At 2 days after the gene transfer the AdCMVBMP-2-infected cells produced 125 ng/ml per 24 h period, while liposome-mediated gene delivery yielded 65 ng/ml, declining to 52 and 36 ng/ml, respectively, within 14 days (data not shown). In addition, coculture experiments with untreated BMSC were performed. Both expression of type I collagen mRNA and positive staining for alkaline phosphatase were detected in the untreated BMSC of the bottom well after 7 days of coculture ( Figure 3 ) irrespective of the gene transfer method used.
New bone formation in vitro
We next investigated whether a transplantation of such BMP-2-producing cells onto periosteal tissue may lead to To determine the duration of transgene expression, the transgenic message was also detected by reverse transcription polymerase chain reaction (RT-PCR) at different time points after gene delivery. BMP-2 mRNA was detectable for 14 days irrespective of the gene transfer method used (Figure 4g ). At 3 days after the transplantation, the transgenic protein was observed predominantly in the transplanted cell layer, however, at later time points, the BMP-2-containing area had extended to neighbouring periosteal cells below the transplanted cell layer ( Figure  4e ). Until day 7 after the transplantation, BMP-2 was predominantly detected in tissues with a graft of genetically modified cells irrespective of the gene transfer method used, but rarely in control tissues with a graft of unmodified BMSC. At 2 weeks after the transplantation, BMP-2 protein was mainly observed in periosteal cells rather than in the transplanted cell layer (Figure 4f ) in all experimental groups including the control group, and no differences in the size of the area of BMP-2-producing cells were evident. At this time point, however, immunohistochemical staining for the bone marker protein osteocalcin indicating mineralization was detected in those tissues, which had been treated with genetically modified BMSC, but rarely in the control group. This staining was seen predominantly around the transplanted cells (Figure 5a , b). In both gene transfer groups, the amount of osteocalcin increased similarly rapidly. At 4 weeks after the transplantation endochondral bone formation had occurred both in the gene transfer groups (Figure 5d , e) and in the control ( Figure  5f ); however, the amount of newly formed bone in the control tissue was much less than in the tissues that had received genetically modified BMSC (Figure 5g -i). Direct demonstration of mineralization by alizarin red staining and immunochemical staining of other bone matrix proteins such as type I collagen and osteopontin confirmed these results (data not shown).
Bone regeneration in critical size defects in vivo
Autologous BMSC obtained from the femur of rats were next modified by adenoviral or liposome-mediated BMP-2 gene transfer and transplanted into circular critical size defects (diameter of 6 mm) in the mandible of these animals, which were killed at different time points after the transplantation. In both groups, BMP-2 production by the transplanted cells continued for more than 2 weeks (data not shown).
Treatment of the defects with AdCMVBMP-2-infected BMSC (experimental group I) resulted in nearly complete bony healing within 4 weeks after the transplantation (Figure 6a , e). The bone defect was found filled with new bone without fibrous tissue engagement, and a bony convergence at the anatomical surface was seen in most animals ( Figure 6a ). No invasion of bone matrix into the surrounding muscle layer was detected microscopically, and the border between newly formed bone and muscle was well defined. The newly formed bone appeared already mature 4 weeks after the treatment, showing a typical trabecular pattern (Figure 6e ). Trichrome-Goldner staining revealed a mature bone matrix throughout the area of the former defect (Figure 7a ), in which the normal distribution of osteocalcin was detected immunohistochemically (Figure 7e ). At 6 weeks after the treatment the defect was completely filled with newly formed bone (Figure 7i , m).
The healing of bone defects that had been treated with BMSC modified by liposome-mediated BMP-2 gene transfer (experimental group II) took slightly longer than in group I. Although a mature bone matrix with a trabecular pattern had formed at the margin of the defect at 4 weeks after the treatment, the central portion of the Figure 4 Expression of the BMP-2 transgene following cell transplantation in vitro. BMSC that had been infected with AdCMVBMP-2 (500 PFU/cell; a, c) or treated with Metafectene-pCMVBMP-2 complexes (1.5 mg DNA/6 ml of the lipid; b, d, e, f) were seeded onto periosteal explants from the rat calvarium. The tissues were harvested at different time points after the transplantation and analysed by in situ hybridization of BMP-2 mRNA and immunohistochemistry. At 3 days after the transplantation, both BMP-2 mRNA (a, b) and BMP-2 protein (c, d) were detectable in the graft irrespective of the gene transfer method used. At 7 days after the transplantation (e) the BMP-2-containing area had extended to neighbouring periosteal cells below the transplanted cell layer. At 2 weeks after the transplantation (f), BMP-2 protein was mainly observed in periosteal cells rather than in the transplanted cell layer ( Â 200 final magnification). For RT-PCR periosteal tissue was harvested 3, 7 or 14 days following cell transplantation. After lysis and homogenization the mRNA was isolated, reversely transcribed and amplified in 35 PCR cycles. The PCR products were analysed by electrophoresis on a 1% agarose gel (g). Expression of human BMP-2 was detectable for at least 2 weeks irrespective of the vector used. Lane 1¼control tissue treated in an identical manner without reverse transcriptase; lane 2¼untreated BMSC; lanes 3, 5, 7¼BMSC infected with AdCMVBMP-2 at 3, 7 or 14 days, respectively; lanes 4, 6 and 8¼BMSC treated with MetafectenepCMVBMP-2 complexes at 3, 7 and 14 days. showed new bone formation in all samples; however, the amount of newly formed bone in the control (i) was significantly less than in the tissues, which had received genetically modified BMSC ( Â 50 final magnification). Figure 6 Bone regeneration in critical size defects in vivo. Autologous BMSC (1 Â 10 6 cells) that had been infected with AdCMVBMP-2 (a, e), treated with Metafectene-pCMVBMP-2 complexes (b, f), or treated with AdLacZ (c, g) were transplanted into circular critical size defects in the rat mandible (diameter of 6 mm). Gross observation 4 weeks after the transplantation showed nearly complete bony healing where the genetically modified cells had been applied (a, b). Radiography revealed a mature trabecular pattern at 4 weeks (e) or 6 weeks (f) after the transplantation. AdLacZ-infected cells adhered to the defect and showed reporter gene expression with maximum X-gal staining after 3 days (c), but had failed to produce a significant amount of new bone matrix by week 8 after the transplantation (g). In defects that had been left untreated bone regeneration, if any, was only seen at the defect margins (d, h). Representative pictures are shown.
Bone
The main difference between the two gene transfer groups was the quantity of the newly formed tissue. The thickness of the new bone in animals that had received adenovirally infected BMSC was significantly greater than that of the neighbouring original bone, whereas the new bone produced following liposome-mediated gene transfer had a similar thickness and shape as the original bone.
In bone defects of control animals, which had received BMSC treated with the b-galactosidase reporter gene vector AdLacZ or untreated BMSC (experimental groups III and IV, respectively), only minor regeneration at the margins of the defect was seen. Transplanted AdLacZinfected cells adhered to the defect and showed reporter gene expression for at least 2 weeks after the transplantation, with maximum staining after 3 days (Figure 6c ), but failed to produce a significant amount of new bone matrix (Figure 6g and Figure 7c , g, k, o) during the 8 weeks of our study. In rare cases, a few focal bone nodules scattered over the area of the defect were observed, but no mature bone matrix was found in these nodules. In defects that had been left untreated (experimental group V) bone regeneration if any was seen only at the defect margins (Figure 6d and h, Figure 7d , h, l, p).
Discussion
A through-and-through bone defect in the rat mandible is a well-established critical size defect model. In several previous studies, circular bone defects with diameters of 4 mm or more failed to heal spontaneously within 16 or 24 weeks. [25] [26] [27] [28] [29] Various therapeutic approaches for the treatment of such critical size defects have been investigated. [28] [29] [30] The use of demineralized bone powder resulted in more than 50% filling up of the defects, 28 and application of rhBMP-2 yielded over 60% defect healing in all cases, with half of the defects (diameter of 5 mm) showing 100% healing. 29 However, administration of a single large dose of BMP-2 protein may also have serious adverse effects, because the protein may spread throughout the patient's body and subsequently accumulate in Figure 7 Detection of new bone matrix in the treated critical size defects. At 4 weeks after the transplantation Trichrome-Goldner staining (a-d) revealed a mature bone matrix throughout the area of the former defect only in those samples, which had been treated with AdCMVBMP-2-infected BMSC (a), whereas in the defects that had received BMSC modified by Liposome-DNA complexes (b) the central portion of the repair tissue was still fibrous at this time point. No significant amount of new bone matrix was observed in defects treated with AdLacZ-infected BMSC (c) or in untreated defects (d). Immunohistochemical detection of the marker protein osteocalcin in neighbouring sections of the same samples (e-h) confirmed these results. At 6 weeks after the treatment both Trichrome-Goldner staining (i-l) and osteocalcin immunohistochemistry (m-p) showed complete bony filling of the defects, which had been treated with AdCMVBMP-2-infected BMSC (i, m) or with BMSC modified by the liposome-DNA complexes (j, n). Again no significant amount of new bone matrix was observed in defects treated with AdLacZ-infected BMSC (k, o) or in untreated defects (l, p). ( Â 25 final magnification).
Bone regeneration by cell-mediated BMP-2 gene transfer J Park et al organs such as kidneys or liver, which may lead to inadvertent bone formation there. This problem also applies to any direct administration of adenoviral BMP-2 vectors, 23 which has been studied on 4 mm-diameter defects and shown to improve bone healing significantly compared with a control virus. 30 The risk may be reduced by protein delivery via cell-mediated gene therapy. In this study, we created 6-mm-diameter defects with a total defect area more than two-fold larger than in the established 4-mm-diameter defects, because larger defects appeared more suitable for a comparison of the efficacy of two gene transfer methods.
Previous gene therapy studies 22, 31 showed that cellmediated BMP-2 gene transfer using the stably transfected mesenchymal progenitor cell line C3H10T1/2 resulted in enhanced bone defect repair in a mice nonunion fracture model. Our study focused on differences in the extent and pattern of new bone formation following liposome-mediated or adenoviral gene transfer. In vitro, the adenoviral vector allowed for more efficient gene transfer than the liposome and led to an even distribution of BMP-2-producing cells throughout the culture vessel, while liposome-mediated gene delivery resulted in a focal population of BMP-2-producing cells. As a previous time-course study 6 of ectopic bone formation in rats had shown that the time point at which bone formation occurred was dependent on the amount of rhBMP-2 present at the injection site, this different gene transfer efficacy is likely to be responsible for the different capabilities of the respective cells to lead to bone formation in vivo. For both adenoviral and liposome-mediated gene transfer, the duration of transgene expression is normally limited to a relatively short period of time. However, for the purpose of bone regeneration by cell-mediated BMP-2 gene therapy such short-term transgene expression may actually be sufficient and even advantageous, although the desired kinetics of expression will depend on the fracture site, nature and extent of the injury, the genetic background, personal habits (eg smoking) and the comorbidity of the patient. In our study, BMP-2 production by the transplanted cells continued for at least 2 weeks irrespective of the vector used, and this proved sufficient to induce successful bone healing at least in our small animal model. Thus, both vectors fulfil the requirements of this particular application.
Since 2 weeks after the transplantation no significant differences in the amounts and distribution of BMP-2 between the gene transfer groups and the control group were detectable anymore, the formation of new bone must have been due to the BMP-2 produced by genetically modified BMSC during the first 7-10 days after the transplantation. This assumption can also be based on the previous results of rhBMP-2 application. In most of these studies bone healing could be achieved with a single-dose administration of rhBMP-2. [6] [7] [8] [9] [10] 14, 29, 32 Sellers et al 33 reported a mean residence time of rhBMP-2 of 8 days with an elimination half-life of 5.6 days in a cartilage defect model. Explanations for the successful repair of bone defects by a protein that is only present for a few days may be the initiation of differentiation cascades or the recruitment of a sufficient number of the required cells already within the first days. 33 However, previous studies found a different pattern of new bone formation between rhBMP-2 application and cell-mediated BMP-2 gene transfer. Lieberman et al 14 noticed that the newly formed tissue following BMP-2 gene transfer was composed of coarse trabecular bone, whereas the bone formed following rhBMP-2 application was thin and lace-like. This observation has been confirmed by others. 22 Lieberman et al 14 explained this difference by the kinetics of the protein release and the use of BMSC as carriers. They postulated that the osteoinductive stimulus associated with BMP-2-producing BMSC might be enhanced because the BMP-2 protein is released continuously. In our study, a mature bone matrix with a normal trabecular pattern was produced following transplantation of the genetically modified autologous BMSC, irrespective of the gene transfer method used. The main difference between the two gene transfer groups was the quantity of the newly formed tissue. In all animals, which had received adenovirally infected BMSC, excessive bone was formed. This, however, was not seen following liposomemediated gene transfer, which resulted in the desired repair tissue with similar thickness and shape as the original bone.
This study also demonstrates that transplanted primary BMSC can be differentiated into an osteoblastic lineage and contribute to bone regeneration via a paracrine pathway. The therapeutic potential of our cell-mediated gene therapy approach may depend mainly on the potency of the transgenic protein to stimulate the differentiation of neighbouring cells. As Riew et al 12 reported, the production of a cytokine from genetically modified cells may have the paracrine effect of inducing the differentiation of neighbouring cells to osteoprogenitor cells. In this study, unmodified BMSC have been shown to differentiate into an osteoblastic lineage under the influence of genetically modified BMSC in coculture, and neighbouring periosteal cells were stimulated to produce bone matrices by transplantation of genetically modified BMSC ex vivo. Periosteum contains both osteoprogenitor and chondroprogenitor cells, which can form either bone or cartilage depending on the conditions. 18 Other previous studies have also shown that orthotopic or heterotopic transplantation of periosteum-derived cells facilitates osteogenesis in different animal models. [34] [35] [36] [37] Harada et al 38, 39 proposed that BMP-2 induces chondroneogenesis from periosteum-derived cells. The results of our transplantation experiments ex vivo suggest that neighbouring cells including periosteal cells and nontransfected BMSC are affected by paracrine mechanisms. BMP-2-producing BMSC may themselves differentiate into osteoprogenitor cells by autocrine activity. This has also been documented in previous studies on a mesenchymal cell line. 21, 22 A combination of bone marrow transplantation and application of rhBMP-2 also suggested a synergistic effect on bone healing. 32 This potential of BMP-2-producing BMSC might be the main reason for our favourable results in vivo obtained even with the less efficient liposome-mediated gene transfer.
Cell-mediated BMP-2 gene therapy may allow for successful treatment of large bone defects, fibrous bony unions or osteoradionecrosis. As liposome-mediated gene transfer has proven sufficient for this purpose and offers significant advantages over any other vector system, such as ease of preparation, theoretically no Bone regeneration by cell-mediated BMP-2 gene transfer J Park et al limitation of the size of the DNA, and less immunological and safety problems, it may represent the best vector system for clinical studies of bone regeneration by BMP-2 gene therapy.
Material and methods
Cell culture
Primary BMSC were harvested from the femur of 16-week-old Wistar rats (Charles River, Sulzfeld, Germany) under sterile conditions by flushing the bone marrow cavity twice with 10 ml of Dulbecco's modified Eagle's medium (DMEM; Gibco, Germany) supplemented with 10% fetal calf serum, L-glutamine (0.35 mg/ml) and penicillin/streptomycin (100 IU/ml). The resulting cell suspension was filtered through a 70 mm filter and transferred into culture vessels. At 1 day later nonadherent cells were removed by careful washing with phosphate-buffered saline (PBS), and the adherent primary cells were cultured for 7 days. The culture medium was replaced every 2 days.
Adenoviral vectors
The first-generation E1-deleted adenoviral vector AdCMVBMP-2, containing human BMP-2 cDNA (a gift from Dr G Gross, Gesellschaft fü r Biochemische Forschung, Braunschweig, Germany) under the control of the CMV promoter was constructed by homologous recombination of the plasmids pACCMVBMP-2 and pJM17 in a 911 helper cell line as described previously, 23 propagated in 911 cells, purified by ultracentrifugation in a caesium chloride gradient, and dialysed against a 10% glycerol-containing storage buffer. The concentrations of the viral stocks, as determined by plaque assays on 911 cells, ranged from 1 Â 10 10 to 3 Â 10 10 PFU/ml. The control vector AdLacZ (obtained from Transgene, Strasbourg, France), carrying a b-galactosidase reporter gene with a nuclear targeting signal under the control of the respiratory syncytial virus (RSV) promoter, was prepared as described previously. 23 Gene transfer assays in vitro BMSC cultured in six-well plates (1.5 Â 10 5 cells/well) were treated with the adenoviral vectors AdCMVBMP-2, AdGFP or AdLacZ or with liposome-DNA complexes, respectively, at subconfluence. Each well was preincubated with 1 ml of serum-free DMEM for 20 min. The respective adenoviral vector (500 PFU/cell) diluted in PBS to a total volume of 50 ml was applied dropwise to the cells, followed by incubation at 371C, 5% CO 2 . At 45 min after the infection, 1 ml of complete culture medium was added to each well. After further incubation for 4 h, the virus-containing medium was replaced by complete culture medium. For liposome-mediated transfection, the plasmids pACCMVBMP-2, pGFP or pLacZ were mixed with Metafectene (Biontex, Munich, Germany; 4 ml/mg of DNA); LipofectAMINE (Invitrogen, Karlsruhe, Germany; 4 ml/mg of DNA) or Geneshuttle (Q-biogene, Heidelberg, Germany; 3.5 ml/mg of DNA) and left standing at room temperature for 15 min, before 160 ml of the liposome-DNA complexes in serum-free DMEM were added dropwise to each well containing 1 ml of DMEM with 5% of FCS. After incubation at 371C for 4 h, the medium was replaced by complete culture medium.
At different time points after infection with AdGFP or transfection with pGFP, respectively, the cells were trypsinized, centrifuged and resuspended in 200 ml of PBS containing 5% FCS. GFP-positive cells were detected and quantified using a fluorescence-activated cell sorter. The supernatants of BSMC treated with AdCMVBMP-2 (500 PFU/cell) or with Metafectene-pACCMVBMP-2 complexes (1.5 mg DNA/6 ml of the lipid) were collected at different time points following infection/transfection and analysed by ELISA to quantify the secretion of BMP-2 as described previously. 23 
Coculture experiments
A coculture of genetically modified BMSC and unmodified BMSC was performed in Transwell six-well plates (Corning Costar). The BMP-2-producing BMSC that had been infected with AdCMVBMP-2 (500 PFU/cell) or treated with Metafectene-pACCMVBMP-2 complexes 24 h prior to the coculture experiment were seeded onto the upper well, while untreated BMSC were plated on the lower well. In control dishes, untreated BMSC were plated both on the upper and the lower wells. The untreated BMSC in the lower wells were harvested after 7 days of coculture with a cell-scraper and analysed by RT-PCR and histochemistry.
Type I collagen mRNA was detected by RT-PCR. The mRNA was isolated using the Oligotex mRNA isolation kit (Qiagen, Hilden, Germany) and reversely transcribed with the First-strand cDNA synthesis kit (Roche, Mannheim, Germany) according to the manufacturer's protocols. PCR using the rat collagen I aI primers 5 0 -CAA GGG TGA GAC AGG CGA AC-3 0 (forward) and 5 0 -CTC GAA CTG GAA TCC ATC GGT-3 (reverse) and rat GAPDH primers was performed as described previously. 40 The PCR products were analysed by electrophoresis on a 1% agarose gel.
Alkaline phosphatase was detected by histochemistry. The cells were fixed with ice-cold methanol and then exposed to 10 mM Tris-HCl (pH 8.4) containing 20 mg/ ml disodium naphthol AS-MX phosphate (Sigma, Taufkirchen, Germany) and 40 mg/ml Fast red TR salt (Sigma) for 30 min at room temperature with shaking. Afterwards they were washed three times with PBS and observed under the microscope.
Cell transplantation in vitro
Genetically modified BMSC were seeded onto periosteal explants from the rat calvarium (2 Â 10 5 cells/cm 2 ), which had been preconditioned in DMEM supplemented with 10% fetal calf serum, L-glutamine (0.35 mg/ml) and penicillin/streptomycin (100 IU/ml). As a control, the same number of untreated BMSC was applied. Following incubation for 2 days at 371C and 5% CO 2 , the medium was replaced by complete culture medium supplemented with ascorbic acid (50 mg/ml) and b-glycerophosphate (10 mM). The periosteal tissues were harvested at 3, 7, 14, 21 or 28 days after the transplantation for analysis by in situ hybridization, alizarin red staining, toluidine blue staining, immunohistochemistry and RT-PCR. The specimens were stained either with 0.3% toluidine blue solution containing 2.5% sodium carbonate for 5 min or with 1% alizarin red dissolved in 0.028% ammoniumhydroxide solution for 5 min and rinsed with aqua dest Bone regeneration by cell-mediated BMP-2 gene transfer J Park et al and hydrochloric acid in ethanol. For RT-PCR, the periosteal tissue was harvested 3, 7 or 14 days after cell transplantation and treated with 0.25% collagenase (Sigma) for 3 h at 371C, followed by centrifugation. The resulting cell pellets were lysed and homogenized, and total RNA was isolated using the RNAeasy mini kit (Qiagen, Hilden, Germany). The mRNA was obtained from 1 mg of each total RNA sample by using the Oligotex mRNA isolation kit (Qiagen, Hilden, Germany).
Reverse transcription was performed with the Firststrand cDNA synthesis kit (Roche, Mannheim, Germany) according to the manufacturer's protocols. The human BMP-2 primers 5 0 -AGC AGG TGG GAA AGT TTT GA-3 0 (forward) and 5 0 -CTC GTC AAG GTA CAG CAT CG-3 (reverse) were used for PCR (35 cycles; 30 s at 951C, 591C and 721C, respectively). The PCR products were analysed by electrophoresis on a 1% agarose gel.
In situ hybridization
A 382 bp fragment of human BMP-2 cDNA obtained by cleavage with the restriction endonuclease BsaAI was transcribed with T7 RNA polymerase to generate an antisense probe. The single-stranded RNA probe was labelled with Digoxigenin using the DIG RNA labelling kit (Roche, Mannheim, Germany) according to the manufacturer's protocols. In situ hybridization was carried out at 561C for 20 h as described previously. 41 Negative controls included RNAse treatment before hybridization and use of either the antisense RNA probe or anti-DIG antibody. All negative controls showed no detectable signal.
Immunochemistry
For immunocytochemistry, cultured BMSC were washed twice with PBS and fixed with 4% paraformaldehyde for 15 min at 41C, followed by careful washing with PBS. Endogenous peroxidase was blocked by incubation with 3% hydrogen peroxide for 10 min. Serum-free blocking agent (DAKO, Hamburg, Germany) was used for blocking of nonspecific protein binding. The cells were then allowed to react with a mouse monoclonal antibody against rhBMP-2 (H3b2, Genetics Institute, Cambridge, USA) for 1 h at room temperature. Following careful washing with PBS, first a biotinylated anti-mouse rabbit IgG (DAKO) and then a streptavidin-HRP complex (DAKO) were applied, which was detected by 3-amino-9-ethylcarbazole (AEC; DAKO).
For immunohistochemistry, periosteal tissues were fixed in 4% paraformaldehyde for 2 h at room temperature, embedded in paraffin and cut into 5 mm sections. Endogenous peroxidase activity and nonspecific protein binding were blocked as described above. BMP-2, osteopontin and osteocalcin were detected using the mouse monoclonal antibody H3b2 (Genetics Institute), a mouse monoclonal antibody against osteocalcin (Takara Shuzo, Shiga, Japan) and a goat polyclonal antibody against osteopontin (Santa Cruz Inc., Santa Cruz, USA), respectively. The detection procedure was performed as described above. Cell nuclei were counterstained with haematoxylin.
Cell transplantation in vivo
In total, 56 Crl:(WI)BR Wistar rats (Charles River, Sulzfeld, Germany) with body weights of approximately 300 g were used. The animals were maintained in airconditioned cages providing a constant temperature of 20-251C with a relative humidity of 40-55% and a lightdark cycle of 12 h, and fed a standard diet ad libitum. Four groups of animals were formed according to the type of cells transplanted: AdCMVBMP-2-infected BMSC (experimental group I, 14 animals), BMSC treated with Metafectene-pACCMVBMP-2 complexes (experimental group II, 14 animals), AdLacZ-infected BMSC (experimental group III, 7 animals), untreated BMSC (experimental groups IV, 7 animals). A fifth group of animals did not receive any cell transplantation (experimental group V, 14 animals).
The animals were anaesthetized with a single intraperitoneal injection of 30 mg ketamine (Ketavet; Pharmacia & Upjohn, Erlangen, Germany) and 3.5 mg xylazine (Rompun; Bayer, Leverkusen, Germany). Following submandibular skin incision and careful dissection of muscle and periosteum, a round through-andthrough critical-size bone defect with a diameter of 6 mm was created in the ramus of the left mandible using a trephine bur (Komet; Gebr. Brasseler, Lemgo, Germany).
Each animal of groups I-IV received 1 Â 10 6 cells that had been treated in vitro as described above, except for the addition of dexamethasone (10 nM) and ascorbic acid (50 mg/ml) to the culture medium, followed by incubation for 18 h prior to the transplantation. The cells were harvested with trypsin/EDTA, centrifuged, resuspended in 30 ml of fresh serum-free DMEM and placed onto a collagen sponge (Braun-Aesculap, Tuttlingen, Germany), which was delivered into the bone defect. The animals of group V received empty collagen sponges. Following cell transplantation, the muscle layers and the skin were closed by resorbable sutures. All procedures were approved by the appropriate Institutional Review Board.
Radiographical, histological and histochemical analysis
